Data from multiple sources - Curated by Marshall Pearce - Last updated 06 June 2017
Added 2 months ago Drug news
Phase III SAHARA study success for SHP 616 Liquid (subcutaneously administered C1 esterase inhibitor [human] Liquid for Injection) to treat Hereditary Angioedema.-Shire plc.
Shire plc announces positive topline Phase III results for the SAHARA study, a global, multi-center, randomized, double-blind, placebo-controlled, partial crossover...
Added 5 months ago Drug news
FDA approves Haegarda (subcutaneous C1-esterase inhibitor) for subcutaneous administration to prevent hereditary angioedema (HAE) attacks in adolescent and adult patients.-CSL Behring
The FDA has approved Haegarda, the first C1 Esterase Inhibitor (Human) for subcutaneous (under the skin) administration to prevent Hereditary...
Added 6 months ago Drug news
Shire announced positive topline Phase III results for the HELP study, a global, multi-center, randomized, double-blind placebo-controlled parallel group trial...
An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.
ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients
This part of the European Fungal Infection Study Group (EFISG) of the European Society of Clinical Microbiology and Infectious Diseases...
Added 4 years ago
Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection.
Rituximab, a monoclonal antibody that targets CD20 on B cells, is now central to the treatment of a variety of malignant and autoimmune disorders.
Added 6 months ago
Human immunoglobulin 10 % with recombinant human hyaluronidase: replacement therapy in patients with primary immunodeficiency disorders
Human immunoglobulin is an established replacement therapy for patients with primary immunodeficiency disorders (PIDs). Recombinant human hyaluronidase (rHuPH20) is a...
Added 3 years ago
Risk factors for oral mucositis in children receiving hematopoietic cell transplantation for primary immunodeficiencies: A retrospective study
OM is a frequent complication for patients undergoing HSCT. The aim of this study was to evaluate the possible risk...
Added 4 years ago